Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sofosbuvir + velpatasvir (Gilead Sciences)
- Development stage
- Approved
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sofosbuvir/velpatasvir (brand name Epclusa) is a fixed-dose combination small molecule antiviral drug developed by Gilead Sciences for the treatment of chronic hepatitis C virus (HCV) infection. It combines two potent direct-acting antivirals: sofosbuvir, a nucleotide analog inhibitor of the NS5B RNA-dependent RNA polymerase, and velpatasvir, a pan-genotypic inhibitor of the NS5A protein. This combination is the first all-oral, single-tablet regimen approved for the treatment of adults and pediatric patients (3 years and older) with HCV genotypes 1 through 6. It is indicated for use in patients without cirrhosis or with compensated cirrhosis, and in combination with ribavirin for those with decompensated cirrhosis. Additionally, it is being investigated in Phase 4 clinical trials for use as post-exposure prophylaxis (PEP) in healthcare workers following high-risk exposures such as needlestick injuries.
- Brand names
- Epclusa
- Other names
- sofosbuvir/velpatasvirsofosbuvir-velpatasvir
02
Targets
NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on sofosbuvir + velpatasvir (Gilead Sciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sofosbuvir + velpatasvir (Gilead Sciences).